

Comorbidity of Fibromyalgia in Primary Knee Osteoarthritis: Potential Impact on Functional Status and Quality of Life [Corrigendum]

Mahgoub MY, Elnady BM, Abdelkader HS, Abdelhalem RA, Hassan WA. *Open Access Rheumatol.* 2020;12: 55–63. The authors apologize for this error.

The authors have advised that Table 1 on pages 58 and 59 is incorrect. The correct table is shown below.

Table 1 Baseline Characteristics of Different Groups

| | Variable | KOA (n=59) Group I | KOA Patients with FM (n=32) Group II | FM (n=30) Group III | P value |
|------------------------------|--|--------------------|--------------------------------------|---------------------|--|
| Demographic | Age (years), mean \pm SD | 53.4 \pm 7.2 | 47.3 \pm 4.6 | 37.5 \pm 6.9 | <0.001* P1<0.001*, p2<0.001*, p3<0.001* |
| | BMI, mean \pm SD | 33.4 \pm 3.1 | 33.3 \pm 3.4 | 29.5 \pm 3.9 | <0.001* p1<0.001*, p2<0.001*, p3=0.8 |
| | Residence (rural: urban) | 34:25 | 22:10 | 18:12 | 0.58 |
| | Marital status (married: not married) | 49:10 | 23:9 | 19:11 | 0.11 |
| | Educational level (literate: illiterate) | 39:20 | 26:6 | 26:4 | 0.07 |
| Clinical | Disease duration (years), median (IQR) | 3 (2-5) | 2 (1-3.5) | 2 (2-3) | 0.07 |
| | KL grades, n (%) | | | | |
| | I | 16 (27.1) | 18 (56.3) | ---- | 0.02* |
| | II | 17 (28.8) | 7 (21.9) | ---- | |
| | III | 26 (44.1) | 7 (21.9) | ---- | |
| | VAS, median (IQR) | 3 (2.0-4.75) | 6 (5-8) | 5 (3-7) | <0.001* p1=0.002*, p2=0.04*, p3<0.001* |
| | PSQI, mean \pm SD | 7.5 \pm 1.7 | 12.5 \pm 2.5 | 9.1 \pm 2.7 | <0.001* P1<0.001*, p2<0.001*, P3<0.001* |
| | PASS20, mean \pm SD | 35.9 \pm 8.4 | 47.8 \pm 10.9 | 40.5 \pm 8.6 | <0.001* p1=0.02*, p2=0.005*, p3<0.001* |
| | BDI-II, median (IQR) | 5 (2-7) | 14 (9-17.5) | 22.5 (18-27) | <0.001* p1<0.001*, p2<0.001*, p3<0.001* |
| Lequesne score, median (IQR) | 5 (4-7) | 7 (5.5-12) | ---- | <0.001* | |
| FIQ, mean \pm SD | ---- | 49.5 \pm 20.7 | 42.8 \pm 13.2 | 0.14 | |

(Continued)

Table I (Continued).

| | Variable | KOA (n=59) Group I | KOA Patients with FM (n=32) Group II | FM (n=30) Group III | P value |
|-----------------|--------------------------|--------------------------|---|---------------------------|---|
| Quality of life | Physical, mean \pm SD | 49.8 \pm 14.7 | 47.6 \pm 14.1 | 62.1 \pm 14.4 | <0.001* p1=<0.001*, p2=<0.001*, p3=0.5 |
| | Cognitive, mean \pm SD | 55.6 \pm 15 | 49.9 \pm 16.6 | 51.3 \pm 14.8 | 0.2 |
| | Affective, mean \pm SD | 53.5 \pm 14.3 | 34.4 \pm 17.3 | 47.6 \pm 15.1 | <0.001* p1=0.07, p2=0.002*, p3<0.001* |
| | Social, mean \pm SD | 50.5 \pm 15.2 | 45.8 \pm 13.8 | 55.2 \pm 12.4 | 0.04* P1=15, p2=0.006*, p3=0.14 |
| | Economic, mean \pm SD | 55.2 \pm 19.1 | 54.8 \pm 22.5 | 60.9 \pm 16.5 | 0.36 |
| | Ego, mean \pm SD | 47.8 \pm 16 | 34.9 \pm 15.9 | 35.9 \pm 14.9 | <0.001* p1=0.001*, p2=0.8, p3<0.001* |
| Medications | Acetaminophen, n (%) | 49 (83) | 20 (62.5) | 15 (50) | 0.004* |
| | NSAIDs, n (%) | 46 (78) | 27 (84.4) | 22 (73.3) | 0.6 |
| | Antidepressant, n (%) | 4 (6.8) | 12 (37.5) | 27 (90) | <0.001* |
| | Gabapentinoids, n (%) | 9 (15.3) | 16 (50) | 24 (80) | <0.001* |
| | Chondroprotctives, n (%) | 46 (78) | 21 (65.6) | 0 (0) | 0.3 |

Notes: P1: between KOA group and FM group; p2: between FM group and KOA patients with FM co-morbidity group; p3: between KOA group and KOA patients with FM co-morbidity group. *p<0.05.

Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; KL, Kellgren and Lawrence; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory; FIQ, Fibromyalgia Impact Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs.

Open Access Rheumatology: Research and Reviews

Dovepress

Publish your work in this journal

Open Access Rheumatology Research and Reviews is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of clinical and experimental rheumatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of rheumatological diseases; Investigation, treatment and management

of rheumatological diseases; Clinical trials and novel pharmacological approaches for the treatment of rheumatological disorders. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/open-access-rheumatology-research-and-reviews-journal>